Dual GIP / GLP-1
Weight management + OSA

FDA-approved tirzepatide for chronic weight management.

Zepbound®

Zepbound® (tirzepatide) once-weekly injection. FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Now available in the multi-dose KwikPen® at the same self-pay price as the vial.

Personalized doses

View more pricing information →

Starting at $449.99/mo

No hidden fees
No membership

Free discreet shipping
FDA-approved
Board-certified doctors

Split your payment into manageable installments with Klarna.

Get started

Important: thyroid C-cell tumor risk. Zepbound® may cause thyroid C-cell tumors. Do not use if you or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Medical consultation required to determine eligibility/if a prescription is clinically appropriate. Results may vary. For full details, important safety information, and restrictions visit: maximustribe.com/safety. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, and KwikPen® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. Maximus is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.

Get started

Weight Loss Protocol Zepbound starting at $449.99/mo

Get started

Proven clinical outcomes.

In a 72-week study of adults with obesity or overweight (without diabetes), Zepbound® showed a clear dose-response curve in mean body weight loss.

15.0%

5 mg dose · mean loss

Mean body weight loss on the 5 mg maintenance dose at 72 weeks vs 3.1% placebo.

SURMOUNT-1 · Eli Lilly · 72 wk

19.5%

10 mg dose · mean loss

Mean body weight loss on the 10 mg maintenance dose. 78.1% of participants achieved ≥10% loss vs 18.8% placebo.

SURMOUNT-1 · Eli Lilly · 72 wk

20.9%

15 mg dose · mean loss

Mean body weight loss on the 15 mg maintenance dose at 72 weeks. 83.5% achieved ≥10% loss; 56.7% achieved ≥20% loss vs 3.1% placebo.

SURMOUNT-1 · Eli Lilly · 72 wk

INDICATION: Obesity / overweight + comorbidity

DURATION: 72 weeks

COMPARATOR: Placebo (-3.1%)

3-YEAR EXTENSION: 22.9% sustained at 15 mg

Get started

Additional FDA indication

First and only Rx for moderate-to-severe OSA in adults with obesity.

Zepbound® is FDA-approved as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

In SURMOUNT-OSA, adults on tirzepatide saw reductions in apnea-hypopnea index (AHI) of up to 62.8% and disease resolution rates of 43.0% to 51.5%.

AHI reduction

Up to 62.8%

SURMOUNT-OSA · Eli Lilly

OSA disease resolution

43.0-51.5%

SURMOUNT-OSA · Eli Lilly

Dual GIP and GLP-1. Once weekly.

Tirzepatide is a single-molecule dual GIP and GLP-1 receptor agonist. Mechanism: activates both GIP and GLP-1 receptors, reducing hunger, slowing gastric emptying, increasing satiety, improving glucose regulation and fat metabolism. GIP may further regulate food intake when added to GLP-1 per nonclinical studies.

Dual receptor activation

Zepbound® activates GIP and GLP-1 receptors. GIP may further regulate food intake when added to GLP-1, per nonclinical studies.

Appetite regulation

Reduces appetite and food intake. Slows gastric emptying so you feel fuller longer.

Titration to maintenance

Start at 2.5 mg, step up every 4 weeks. Maintenance doses are 5, 10, 12.5, or 15 mg.

Side effects

Contact your provider immediately if you have these symptoms. Regular monitoring may be needed to track your response to treatment.

Common side effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain

Indigestion
Injection-site reactions
Feeling tired
Belching
Hair loss
Heartburn

Rare, but serious side effects may include:

Acute pancreatitis (including fatal, hemorrhagic, necrotizing)
Acute gallbladder disease
Acute kidney injury (typically secondary to dehydration)
Severe gastrointestinal disease / delayed gastric emptying
Hypoglycemia (especially with insulin or sulfonylureas)
Hypersensitivity reactions including anaphylaxis and angioedema
Pulmonary aspiration during anesthesia or deep sedation (delayed gastric emptying)
Suicidal behavior and ideation (monitor)
Diabetic retinopathy complications (in T2D clients with pre-existing retinopathy)
Thyroid C-cell tumors (rodent data). Boxed warning class effect: contraindicated in clients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Is Zepbound® right for you?

Best for people who

Adults seeking the strongest available weight-loss outcome in a brand-name SKU
Adults with obesity and moderate-to-severe OSA (cross-listed indication)
Adults with pre-diabetes and obesity who want T2D progression prevention
Clients who plateaued on a semaglutide SKU and want a tirzepatide trial
Clients comfortable with weekly subcutaneous injection

Tirzepatide vs semaglutide. 20.2% vs 13.7% mean body weight loss.

In SURMOUNT-5, a 72-week head-to-head trial sponsored by Eli Lilly, adults on Zepbound® (tirzepatide) achieved 20.2% mean body weight loss, compared with 13.7% for adults on Wegovy® (semaglutide).

Medical requirements

Not for clients with type 1 diabetes
No history of medullary thyroid carcinoma or MEN 2 syndrome
Not currently pregnant or breastfeeding
No severe gastrointestinal disease
No concurrent usage of other tirzepatide products or any GLP-1 receptor agonist

It's easy to get started.

Complete your evaluation

Answer a few health questions online. Takes about 5 minutes. No appointment needed, no waiting rooms.

Physician review

A board-certified physician reviews your information and determines if tirzepatide is right for you.

Treatment delivered

If prescribed, your medication ships directly to your door in discreet, unmarked packaging.

Start my treatment

Weight Loss Treatment FAQs

What's the difference between the KwikPen® and the vial?

The KwikPen® holds all four weekly doses for the month in one multi-dose pen. The vial is a single-dose presentation. Both contain the same medication at the same self-pay price via LillyDirect. The KwikPen® means one device per month instead of four separate injections from a vial and syringe.

Zepbound® vs Wegovy®— which loses more weight?

In SURMOUNT-5, a 72-week head-to-head trial sponsored by Eli Lilly, average body weight loss was 20.2% on Zepbound® vs 13.7% on Wegovy®. Waist circumference reduction was 7.2 inches vs 5.1 inches. Wegovy® is the only one of the two with the FDA-approved cardiovascular risk reduction indication. The right choice depends on your goals and clinical history.

What is the OSA indication?

Zepbound® is FDA-approved as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. In SURMOUNT-OSA, AHI was reduced by up to 62.8%, with OSA disease resolution in 43.0% to 51.5% of adults studied.

How long do results last?

In a 3-year extension of SURMOUNT-1, adults sustained an average 22.9% body weight loss on the 15 mg dose. As with any medication for chronic conditions, maintenance is part of the protocol.

What about pre-diabetes?

In a SURMOUNT-1 extension in adults with pre-diabetes and obesity or overweight, Zepbound® showed a 94% reduction in the risk of progression to type 2 diabetes vs placebo. This is reported as a study observation in the SURMOUNT-1 extension data set.